SK Inc. is set to spark innovative ideas and identify new business opportunities with its global strategy and growth roadmap at an event attended by over 50 partners. Joining the event are newly appointed executives to lead SK’s biopharmaceutical businesses, ready to promote the competitiveness of K-bio and provide insight into its remarkable achievements in the US, Europe and Korea markets. It’s sure to be an exciting event that will bring out the best in SK Inc.!
SK Inc., the strategic investment holding company of South Korea’s SK Group, is joining forces with its life science subsidiaries – SK biopharmaceuticals and SK pharmteco – to host a networking event in the United States, the biggest bio and pharmaceutical market in the world. The aim of this event is to expand their global partnerships and collaborations.
SK Inc. is excited to invite 100 executives from over 50 companies to the SK Bio Night on January 11, at the Four Seasons Hotel in San Francisco, US. This exclusive gathering aims to bring SK’s global partners and investment companies together to foster mutually beneficial collaboration and gain an understanding of SK’s current priorities. Don’t miss this opportunity to discover new partnerships and discover the potential of SK.
SK Inc. and its affiliates are thrilled to introduce their newly appointed executives, who will be hosting the event. Dong-hyun Jang, CEO and Vice Chairman of SK Inc., Joerg Ahlgrimm, CEO of SK pharmteco, Dong-hoon Lee, CEO of SK biopharmaceuticals, and Yeon-tae Kim, Head of SK Bio Investment Center, will be showcasing how their respective companies are making strong inroads in the global biopharmaceutical sector. With new leadership in place, SK biopharmaceuticals, SK pharmteco and SK Bio Investment Center are all gearing up to explore new business opportunities and strengthen collaborations with investors and partners.
Yeon-tae Kim, Head of Bio Investment Center at SK Inc., will be discussing the company’s strategic vision for broadening their portfolio beyond small-molecule drugs and how they have strategically optimized their business model to expand their presence in the global biopharmaceuticals space.
Dong-hoon Lee, CEO of SK biopharmaceuticals, will provide a comprehensive overview on its anti-seizure medication cenobamate, now available in the United States under the brand name XCOPRI®. Get ready to be informed on the company’s cutting-edge pipelines and future roadmap that will help increase SK biopharmaceuticals’ global business portfolio and add to its value.
SK pharmteco is making waves in the cell and gene therapy (CGT) sector, an up-and-coming growth market in the contract development and manufacturing organization (CDMO) business. At an upcoming investor and partner event, CEO Joerg Ahlgrimm will showcase SK pharmteco’s business strategy and vision as a global CDMO, demonstrating the company’s impressive competitiveness in the industry.
SK Inc. has achieved remarkable success in becoming a major player in the biopharmaceutical industry. By implementing a comprehensive localization strategy targeting the world’s biggest markets – the US and Europe – the company has been able to bolster its competitiveness through the development of new small-molecule drugs and CGT CDMO business. The results have been truly impressive.
SK Inc. has consistently invested in the biopharmaceutical industry, scaling its business with strategic acquisitions such as the purchase of Bristol Myers Squibb’s Ireland plant in 2017 and AMPAC Fine Chemicals of the US in 2018. To further strengthen their global reach, SK pharmteco was established in 2019 as an integrated CDMO company. In 2021, SK Inc. entered the CGT CDMO business with the acquisition of Yposkesi of France through SK pharmteco and in 2022, became the second largest shareholder of Center for Breakthrough Medicine (CBM), an American CGT CDMO, solidifying their position in the biopharmaceutical industry.
SK pharmteco has carved out a global presence as a CDMO with five research and development centers and eight production facilities spanning the U.S, Europe and Korea. The company has seen remarkable growth, with sales exceeding 1 trillion won (approximately USD 780 million, based on preliminary results) and a customer base that accounts for 95% of its global reach. With these impressive results, SK pharmteco is well-positioned to continue its journey of growth and success.
SK Inc. is thrilled to host SK Bio Night, a unique event designed to explore and create meaningful partnerships and investment opportunities across the globe, including the U.S.! Yeon-tae Kim, Head of SK Bio Investment Center, believes that building long-term relationships are paramount to achieving the company’s objectives and is confident that this event will open up a range of opportunities for growth in markets like the U.S. and Europe. Let’s join forces and make this a success!